Pre-IPO Fangzhou Inc. (PHIP Updates) - Some Points Worth the Attention
Fangzhou faces challenges with decreasing drug price due to VBP/NRDL negotiation. The internal disputes, litigation, cash flow pressure will lead...
HSCI Index Rebalance Preview and Stock Connect: Potential Changes in March 2025
There could be 78 changes for the HSCI in March. That could result in 57 changes to the Southbound Stock Connect list and also have implications...
Quiddity Leaderboard Hang Seng Biotech Dec 24: Positive Flows for Beigene and Innovent Biologics
QuantumPharm (2228 HK) and Fangzhou (6086 HK) are expected ADDs. 3D Medicines (1244 HK) and CARSgen Therapeutics (2171 HK) are expected DELs.
Quiddity Leaderboard Hang Seng Biotech Dec 24: Two Changes Expected + Capping Flows
Assuming the two index changes expected in this insight take place, there will be US$33mn capping flow which translates to a turnover of 2.8%. Five...
No more insights